Cost Effectiveness of Ramipril in Patients at High Risk for Cardiovascular Events

No abstract is available for this paper.

• Publication year

  2012

• Venue

  PharmacoEconomics (Auckland)

• Publication date

  Unknown publication date

• Fields of study

  Medicine, Economics

• Identifiers
  DOI 10.2165/00019053-200422150-00001PMID 15449961
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Cost Effectiveness of Ramipril in Patients with Non-Diabetic Nephropathy and Hypertension

  2012cited by this paper
• Economic Evaluation of Specific Immunotherapy Versus Symptomatic Treatment of Allergic Rhinitis in Germany

  2012cited by this paper
• Kosten-Wirksamkeits-Analyse der Reinfarktprophylaxe mit niedrig dosierter Acetylsalicylsäure: Modellrechnung

  2005cited by this paper
• Cost Implications of the Use of Ramipril in High-Risk Patients Based on the Heart Outcomes Prevention Evaluation (HOPE) Study

  2003cited by this paper
• Economic Impact of Ramipril on Hospitalization of High-Risk Cardiovascular Patients

  2003cited by this paper
• Teubner-Taschenbuch der Mathematik

  2003cited by this paper
• Ramipril for the Prevention and Treatment of Cardiovascular Disease

  2003cited by this paper
• Cost implications of the use of ramipril in high-risk patients based on the Heart Outcomes Prevention Evaluation (HOPE) study.

  2003cited by this paper
• Physicians' interpretation of "class effects": a need for thoughtful re-evaluation.

  2002cited by this paper
• The cost‐effectiveness of ramipril in the treatment of patients at high risk of cardiovascular events: a Swedish sub‐study to the HOPE study

  2002cited by this paper
• The Heart Outcomes Prevention Evaluation study: angiotensin-converting enzyme inhibitors: are their benefits a class effect or do individual agents differ?

  2001cited by this paper
• Cost effectiveness of ramipril treatment for cardiovascular risk reduction

  2001cited by this paper
• [Costs of type 2 diabetes in Germany. Results of the CODE-2 study].

  2001cited by this paper
• Clinical reality of coronary prevention guidelines: a comparison of EUROASPIRE I and II in nine countries

  2001cited by this paper
• Effects of Ramipril on Coronary Events in High-Risk Persons: Results of the Heart Outcomes Prevention Evaluation Study

  2001cited by this paper
• Blood-pressure reduction and cardiovascular risk in HOPE study.

  2001cited by this paper
• Ramipril and the development of diabetes.

  2001cited by this paper
• Kosten des Typ-2-Diabetes in Deutschland

  2001cited by this paper
• Clinical reality of coronary prevention guidelines: a comparison of EUROASPIRE I and II in nine countries. EUROASPIRE I and II Group. European Action on Secondary Prevention by Intervention to Reduce Events.

  2001cited by this paper
• Should an angiotensin-converting enzyme inhibitor be standard therapy for patients with atherosclerotic disease?

  2001cited by this paper
• The HOPE study: comparison with other trials of secondary prevention.

  2001cited by this paper
• [Cost effectiveness of pravastatin in secondary coronary prevention in patients with myocardial infarct or unstable angina in Germany. An analysis on the basis of the LIPID trial].

  2000cited by this paper
• Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Heart Outcomes Prevention Evaluation Study Investigators.

  2000cited by this paper
• Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients.

  2000cited by this paper
• Kosteneffektivität von Pravastatin in der koronaren Sekundärprävention bei Patienten mit Myokardinfarkt oder instabiler Angina pectoris in Deutschland Eine Analyse auf der Grundlage der LIPID-Studie

  2000cited by this paper
• Class effects and evidence‐based medicine

  2000cited by this paper
• The anti‐ischemic potential of angiotensin‐converting enzyme inhibition: Insights from the heart outcomes prevention evaluation trial

  2000cited by this paper
• Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Heart Outcomes Prevention Evaluation Study Investigators.

  2000cited by this paper
• Heart Outcomes Prevention Evaluation Study Investigators. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. N Engl J Med 2000;342:145-53.

  2000cited by this paper
• Economic evaluation of ramipril in the treatment of patients at high risk for cardiovascular events

  2000cited by this paper
• Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators.

  2000cited by this paper
• [Costs of coronary heart diseases over the remaining life time in coronary heart disease cases--an analysis of the current status of coronary heart disease cases in Germany from the social perspective].

  1999cited by this paper
• Kosten koronarer Herzkrankheiten über die verbleibende Lebenszeit von KHK-Fällen – Eine Analyse des aktuellen Bestandes an KHK-Fällen in Deutschland aus gesellschaftlicher Perspektive

  1999influential reference
• Cost-effectiveness analysis of ramipril in heart failure after myocardial infarction. Economic evaluation of the Acute Infarction Ramipril Efficacy (AIRE) study for Germany from the perspective of Statutory Health Insurance.

  1998cited by this paper
• Pharmakoökonomische Bewertung von Pravastatin in der Sekundärprävention der koronaren Herzkrankheit bei Patienten mit durchschnittlichen Cholesterinwerten

  1998cited by this paper
• [Pharmacoeconomic evaluation of pravastatin in the secondary prevention of coronary heart disease in patients with average cholesterol levels. An analysis for Germany based on the CARE study].

  1998cited by this paper
• Cost-Effectiveness Analysis of Ramipril in Heart Failure after Myocardial Infarction

  1998cited by this paper
• Book Review: Cost-effective diagnosis and treatment of coronary heart disease. Topics in cardiac cardiology

  1998cited by this paper
• Prevention of coronary heart disease in clinical practice. Recommendations of the Second Joint Task Force of European and other Societies on coronary prevention.

  1998cited by this paper
• The Cost Effectiveness of Acamprosate in the Treatment of Alcoholism in Germany

  1998cited by this paper
• Evidence-based medicine and ACE inhibition.

  1998cited by this paper
• [Cost-effectiveness analysis of prevention of reinfarction using low-dose acetylsalicylic acid; model calculation].

  1997cited by this paper
• Monte Carlo: Concepts, Algorithms, and Applications

  1997cited by this paper
• Die Wirtschaftlichkeit von Arzneimitteltherapien am Beispiel von Pravastatin

  1997cited by this paper
• [Economic aspects of drug therapy exemplified by pravastatin. A socioeconomic analysis of cholesterol synthase enzyme inhibition in coronary heart disease patients].

  1997cited by this paper
• The future of pharmacoeconomics: a commentary.

  1997cited by this paper
• Ökonomische Analyse der Sekundärprävention der koronaren Herzkrankheit mit Simvastatin (Zocor®) in Deutschland

  1997cited by this paper
• [Economic analysis of secondary prevention of coronary heart disease with simvastatin (Zocor) in Germany].

  1997cited by this paper
• The HOPE (Heart Outcomes Prevention Evaluation) Study: the design of a large, simple randomized trial of an angiotensin-converting enzyme inhibitor (ramipril) and vitamin E in patients at high risk of cardiovascular events. The HOPE study investigators.

  1996cited by this paper
• [Recommendations of the German Society of Clinical Pharmacology and Therapy for implementing and evaluating pharmaco-economic studies].

  1995cited by this paper
• Prevention of coronary heart disease in clinical practice

  1994cited by this paper
• Prevention of coronary heart disease in clinical practice. Recommendations of the Task Force of the European Society of Cardiology, European Atherosclerosis Society and European Society of Hypertension.

  1994cited by this paper
• Statistical Analysis of Epidemiologic Data.

  1993cited by this paper
• Statistical Analysis of Epidemiologic Data

  1993cited by this paper
• Discounting of Health Benefits in the Pharmacoeconomic Analysis of Drug Therapies

  1992cited by this paper
• Simulation: A Statistical Perspective

  1992cited by this paper
• Methods for the economic evaluation of health care programmes

  1987cited by this paper
• A convenient approximation of life expectancy (the "DEALE"). II. Use in medical decision-making.

  1982cited by this paper
• A convenient approximation of life expectancy (the "DEALE"). I. Validation of the method.

  1982cited by this paper

• Features of postoperative therapy in patients with type ІІ diabetes

  2020cites this paper
• Modern Management and Diagnosis of Hypertension in the United Kingdom: Home Care and Self-care.

  2016cites this paper
• The cost-effectiveness of secondary prevention of atherothrombotic disease in Western Australia

  2015cites this paper
• NATIONAL EVIDENCE-BASED GUIDELINE ON SECONDARY PREVENTION OF CARDIOVASCULAR DISEASE IN TYPE 2 DIABETES Blood pressure lowering , lipid modification and anti-thrombotic therapy

  2015cites this paper
• Cost-effectiveness of zofenopril in patients with left ventricular systolic dysfunction after acute myocardial infarction: a post hoc analysis of SMILE-4

  2013cites this paper
• Cost-effectiveness of zofenopril in patients with left ventricular systolic dysfunction after acute myocardial infarction: a post hoc analysis of SMILE-4

  2013cites this paper
• Pharmacoeconomics of Angiotensin II Antagonists in Type 2 Diabetic Patients with Nephropathy

  2012cites this paper
• Ramipril/Felodipine Extended-Release Fixed-Dose Combination

  2012cites this paper
• Cost-effectiveness of enzyme replacement therapy for Fabry disease

  2012cites this paper
• Costs of Stroke Using Patient-Level Data: A Critical Review of the Literature

  2009cites this paper
• Determining the cost-effectiveness of preventing cardiovascular disease: are estimates calculated over the duration of a clinical trial adequate?

  2008cites this paper
• Estimating the Cost Effectiveness of Ramipril used for Specific Clinical Indications

  2007cites this paper
• Pharmaco-economic issues for diabetes therapy.

  2007cites this paper
• Long-term cost-effectiveness of clopidogrel in patients with acute coronary syndrome without ST-segment elevation in Germany

  2007cites this paper
• Should angiotensin-converting enzyme-inhibitors be used to improve outcome in patients with coronary artery disease and 'preserved' left ventricular function?

  2006cites this paper
• Cost-effectiveness in Italy of preventive treatment with ramipril in patients at high risk of cardiovascular events

  2005cites this paper
• Ramipril/felodipine extended-release fixed-dose combination: a review of its use in the management of essential hypertension.

  2005cites this paper